1374248-77-7
- Product Name：Ubrogepant
- Molecular Formula：C29H24F3N5O3
- Purity：99%
- Molecular Weight：549.552
Product Details:
CasNo： 1374248-77-7
Molecular Formula： C29H24F3N5O3
Factory Supply Top Purity 99% Ubrogepant 1374248-77-7 Safe Shipping
- Molecular Formula:C29H26F3N5O3
- Molecular Weight:549.552
- Boiling Point:729.4±60.0 °C(Predicted)
- PKA:11.08±0.20(Predicted)
- PSA：104.29000
- Density:1.45±0.1 g/cm3(Predicted)
- LogP:2.47340
Ubrogepant(Cas 1374248-77-7) Usage
|
Description |
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist. It acts by blocking the action of CGRP, a potent vasodilator believed to play a role in the development of migraine headaches. By inhibiting CGRP, ubrogepant helps alleviate migraine symptoms. |
| Uses |
Ubrogepant is indicated for the acute treatment of migraine headaches in adults. It is specifically designed to relieve pain associated with migraine attacks and is not intended for preventing migraine episodes. It is available in oral form and is taken with a glass of water, with or without food. |
1374248-77-7 Relevant articles
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss，Richard B Lipton，David W Dodick，Nicole Dupre，David Michelson
, Cephalalgia2016/08/22
A total of 527 participants received ubrogepant and 113 received placebo. A positive response trend in the proportion of participants achieving two-hour pain freedom was demonstrated (p<0.001). Ubrogepant 100mg was significantly superior to placebo for two-hour pain freedom (25.5% vs 8.9%) but not for two-hour headache response.
Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant
Yasuda, Nobuyoshi,Cleator, Ed,Kosjek, Birgit,Yin, Jianguo,Xiang, Bangping,Chen, Frank,Kuo, Shen-Chun,Belyk, Kevin,Mullens, Peter R.,Goodyear, Adrian,Edwards, John S.,Bishop, Brian,Ceglia, Scott,Belardi, Justin,Tan, Lushi,Song, Zhiguo J.,Dimichele, Lisa,Reamer, Robert,Cabirol, Fabien L.,Tang, Weng Lin,Liu, Guiquan
, p. 1851 - 1858 (2017/11/24)
The development of a scalable asymmetric...
Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
V. Battini，C. Carnovale，E. Clementi，M. Sessa
Expert opinion on drug safety 2023-06-09
RORs of all AEs related to ubrogepant and rimegepant in FAERS were calculated in comparison with those related to erenumab. Drug-event pairs with a frequency≤2, were removed according to European Medicine Agency (EMA)'s procedures.
1374248-77-7 Process route
-
![(S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid](/upload/2024/1/061a3aac-a20a-435c-8f55-e396dae695b6.png)
- 1375541-21-1
(S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid
-
- 1375470-88-4
(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-aminium hydrochloride
-
![(6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide](/upload/2024/1/b6c8fb03-905d-48f8-9986-8c29101d54ee.png)
- 1374248-77-7
(6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide
| Conditions | Yield |
|---|---|
|
With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 23 ℃; for 3h;
|
-
- 1375541-21-1
(S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid
-
- 1375470-88-4
(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-aminium hydrochloride
-
![(6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxamide](/upload/2024/1/ced9a0df-f286-4a24-abe6-d9e82e102024.png)
- 1374248-77-7
(6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxamide
| Conditions | Yield |
|---|---|
|
(S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid; (3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-aminium hydrochloride; With 2-hydroxy-pyridine N-oxide; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In water; acetonitrile; at 20 ℃; pH=6 - 6.5;
With water; In ethanol;
|
95% |
|
With (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; Reagent/catalyst; Solvent;
|
1374248-77-7 Upstream products
-
1455358-16-3
(S)-1‘-(tert-butyl)-2’-oxo-1‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxylic acid
-
1375541-21-1
(S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid
-
1375470-88-4
(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-aminium hydrochloride
-
1456804-09-3
C23H28ClN3O3
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
VericiguatCAS：1350653-20-1
-
Bictegravir SodiumCAS：1807988-02-8
